礼邦医药-B(09637)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09637 礼邦医药-B

国庆日休市 09-30 16:08:26

24.980

+0.280

+1.13%

最高25.780	最低24.560	成交量45.97万
今开24.960	昨收24.700	日振幅4.94%
总市值86.93亿	流通市值58.95亿	总股本3.48亿
成交额1,154万	换手率0.19%	流通股本2.36亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09637","market":"HK","secType":"STK","nameCN":"礼邦医药-B","latestPrice":24.98,"timestamp":1790755706225,"preClose":24.7,"halted":0,"volume":459734,"delay":0,"changeRate":0.011336032388664014,"floatShares":236000000,"shares":348000000,"eps":-3.071284,"marketStatus":"国庆日休市","change":0.28,"latestTime":"09-30 16:08:26","open":24.96,"high":25.78,"low":24.56,"amount":11544552,"amplitude":0.049393,"askPrice":25.28,"askSize":3300,"bidPrice":24.98,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-2.326,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790904600000},"marketStatusCode":7,"adr":0,"listingDate":1782662400000,"exchange":"SEHK","adjPreClose":24.7,"openAndCloseTimeList":[[1790731800000,1790740800000],[1790744400000,1790755200000]],"volumeRatio":1.0944484120534366,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09637","defaultTab":"news","newsList":[{"id":"2671296172","title":"港股异动 | 礼邦医药-B(09637.HK)午后涨近8% AP308/PKU308获美国FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2671296172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671296172?lang=zh_cn&edition=full","pubTime":"2026-09-29 14:40","pubTimestamp":1790664029,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1161","BK1574","09939","09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669130755","title":"港股异动 | 礼邦医药-B(09637.HK)涨超8% AP308治疗IgAN新药申请获FDA批准 已于肾脏医学领域验证治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2669130755","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669130755?lang=zh_cn&edition=full","pubTime":"2026-09-21 14:12","pubTimestamp":1789971124,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1161","09939","BK1191","09637","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173874044","title":"礼邦医药-B 2026年中期财报：营收1.04亿元，经调整净亏损1.30亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1173874044","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173874044?lang=zh_cn&edition=full","pubTime":"2026-09-17 20:42","pubTimestamp":1789648920,"startTime":"0","endTime":"0","summary":"2026年上半年，礼邦医药-B录得营业收入1.04亿元，同比上升761.2%。经调整净亏损1.30亿元，相比上年同期的1.49亿元减亏12.6%。同期毛利约0.91亿元，毛利率从上年同期的43.4%提升至87.5%。报告期内，研发开支为1.41亿元，同比增长28.4%，占营业收入的比重约为135.7%。销售及管理费用均有不同程度提升，其中销售开支同比增长20.7%，管理费用则增长108.9%。经营活动现金流方面，本期净流出约1.85亿元，较上年同期的1.39亿元净流出规模扩大。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"礼邦医药-B 2026年中期财报：营收1.04亿元，经调整净亏损1.30亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667619385","title":"港股异动 | 礼邦医药-B(09637)午后飙升逾17% AP308治疗IgA肾病新药临床申请获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667619385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667619385?lang=zh_cn&edition=full","pubTime":"2026-09-15 13:36","pubTimestamp":1789450580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼邦医药-B午后飙升逾17%。消息面上，礼邦医药近日宣布，AP308用于治疗IgA肾病的新药临床试验申请近日获美国食品药品监督管理局批准。公司计划于近期启动AP308的首次人体临床试验。AP308的IND获批标志着这一首创新药由临床前研究迈入临床开发阶段。公告指出，IgA肾病是全球最常见的原发性肾小球肾炎，2025年全球患者约950万人，其中中国约510万人，占全球过半。约60%中国患者于确诊后15年内进展至终末期肾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09637","VXUS","BK1161","09939","BK1574","BK4585","159938","BK4588","LABU","BK1515","KCAI","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165566607","title":"礼邦医药-B获美国FDA批准AP308新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1165566607","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165566607?lang=zh_cn&edition=full","pubTime":"2026-09-08 23:32","pubTimestamp":1788881551,"startTime":"0","endTime":"0","summary":"9月8日（路透社）——礼邦医药-B（Alebund Pharmaceuticals (Jiangsu) Ltd，股票代码：9637.HK）今日发布公告，其用于治疗IgA肾病的在研新药AP308的临床试验申请（IND）已获得美国食品药品监督管理局（FDA）的批准。这一里程碑式的进展，标志着礼邦医药在肾脏疾病领域的创新药物研发管线迈出了关键一步，为其后续的临床开发铺平了道路。随着该申请的获批，礼邦医药将得以在美国推进AP308的临床研究计划，进一步评估其安全性和有效性。此次FDA的放行，不仅为AP308的全球多中心临床试验奠定了基础，也为公司在该适应症领域的长期布局注入了强劲动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665378596","title":"礼邦医药-B：AP308治疗IgA肾病新药临床申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665378596","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665378596?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:20","pubTimestamp":1788870000,"startTime":"0","endTime":"0","summary":"9月8日，礼邦医药-B（09637）发布公告，公司自主研发的同类首创工程化重组IgA蛋白酶AP308，其新药临床试验申请已获FDA批准，将启动用于治疗IgA肾病的首次人体临床试验。公告指出，IgA肾病是全球最常见的原发性肾小球肾炎，2025年全球患者约950万人，其中中国约510万人，占全球过半。约60%中国患者于确诊后15年内进展至终末期肾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609083868261729.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609083868261729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK4588","LABU","BK1161","BK1574","BK4585","09637","09939","159938","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112664296","title":"礼邦医药-B（09637）AP308获美国FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1112664296","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112664296?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:12","pubTimestamp":1788869569,"startTime":"0","endTime":"0","summary":"2026年9月8日，礼邦医药（江苏）股份有限公司公告称，其同类首创工程化重组IgA蛋白酶AP308的治疗性新药临床试验申请已获美国食品药品监督管理局批准，公司将启动AP308用于治疗IgA肾病的首次人体临床试验。据公司披露，AP308是首个获准开展临床试验的IgA蛋白酶类IgAN候选药物。公司持有AP308全球开发、生产及商业化权利。公司表示，将于近期启动AP308首次人体临床试验，以验证其在直接清除肾小球致病性IgA免疫复合物方面的安全性与疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195070981","title":"礼邦医药-B：AP308治疗IgA肾病获美国FDA临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1195070981","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195070981?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:01","pubTimestamp":1788868873,"startTime":"0","endTime":"0","summary":"礼邦医药（Jiangsu）近日宣布，其用于治疗IgA肾病的在研新药AP308已获得美国食品药品监督管理局（FDA）的临床试验申请批准。这一进展标志着该候选药物在研发进程中迈出了关键一步，为后续临床研究的推进铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665349337","title":"港股异动 | 礼邦医药-B(09637.HK)涨超6% 纳入港股通及恒生综合指数落地 美信罗销售同比增约105% 商业化兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2665349337","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665349337?lang=zh_cn&edition=full","pubTime":"2026-09-08 10:16","pubTimestamp":1788833785,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09637","BK1515","BK1161","BK1191","09939","BK1574","HSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398982","title":"礼邦医药-B公布H股获纳入港股通及恒生综合指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398982","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398982?lang=zh_cn&edition=full","pubTime":"2026-09-07 08:50","pubTimestamp":1788742200,"startTime":"0","endTime":"0","summary":"模拟交易客户端礼邦医药-B公布，据港股通的相关安排及调整，公司H股获纳入港股通合资格证券名单，将自2026年9月7日（星期一）起生效。H股获纳入港股通乃基于其获纳入恒生综合指数。董事会认为，H股获纳入港股通及恒生综合指数，反映了资本市场对公司价值及长期发展前景的认可，并将有助于进一步扩大公司的投资者基础，提升H股的交易流动性。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-09-07/doc-iniqyeua9585261.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["FLHK","HSCI","BK1515","09939","09637","BK1574","159938","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122886210","title":"礼邦医药-B（09637）H股获纳入港股通与恒生综合指数 9月7日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1122886210","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122886210?lang=zh_cn&edition=full","pubTime":"2026-09-04 21:35","pubTimestamp":1788528943,"startTime":"0","endTime":"0","summary":"礼邦医药-B9月4日公告称，公司H股已被纳入港股通合资格证券名单，生效日期为2026年9月7日。届时，中国内地合资格投资者可通过港股通渠道直接买卖该公司H股。根据恒生指数有限公司于2026年8月21日公布的截至2026年6月30日的恒生指数系列季度检讨结果，礼邦医药-B H股已被纳入恒生综合指数成份股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664332059","title":"礼邦医药-B(09637)H股获纳入港股通及恒生综合指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2664332059","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664332059?lang=zh_cn&edition=full","pubTime":"2026-09-04 21:34","pubTimestamp":1788528840,"startTime":"0","endTime":"0","summary":"H股获纳入港股通乃基于其获纳入恒生综合指数。根据恒生指数有限公司于2026 年8月21日公布的截至2026年6月30日的恒生指数系列季度检讨结果，H股获纳入恒生综合指数成份股，有关变动已于2026年9月4日(星期五)收市后实施，并将自 2026年9月7日(星期一)起生效。董事会认为，H股获纳入港股通及恒生综合指数，反映了资本市场对公司价值及长期发展前景的认可，并将有助于进一步扩大公司的投资者基础，提升H股的交易流动性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FLHK","HSCI","BK1515","09939","09637","BK1574","159938","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179511746","title":"礼邦医药-B8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1179511746","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1179511746?lang=zh_cn&edition=full","pubTime":"2026-09-03 16:55","pubTimestamp":1788425739,"startTime":"0","endTime":"0","summary":"礼邦医药(江苏)股份有限公司于2026年9月3日公布了2026年8月的股份变动月报表。根据公告显示，公司注册股本为人民币348,365,531元，其中包含两类普通股，分别为H股和内资股。两类股份在当月均未发生新增发行、购回、注销或库藏股变动，已发行股份数及注册股本较上月保持不变。截至8月末，礼邦医药(江苏)股份有限公司总股本维持在235,635,489股H股及112,730,042股内资股，合计348,365,531股。公司确认截至8月末，其符合香港联交所规定的最低公众持股量要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662725814","title":"礼邦医药-B(09637)中报深读：肾病赛道的成长复利","url":"https://stock-news.laohu8.com/highlight/detail?id=2662725814","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662725814?lang=zh_cn&edition=full","pubTime":"2026-08-27 07:56","pubTimestamp":1787788588,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月26日，礼邦医药上市后首份中期业绩交出亮眼答卷：收入规模增至去年同期的8.6倍。在这一全球坐标下，礼邦的首份中报勾勒出一家中国垂直专科Biopharma的成长轮廓。2026 年 8 月，其中国新药上市申请已获国家药监局受理;全球 III 期多区域临床试验也已完成全部患者入组。目前，该产品已获国家药监局突破性治疗药物认定，全球 IIb 期临床已完成首例受试者随机化并给药。AP303 与 AP308 则代表礼邦的 “长期成长高度”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1486671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1191","09637","BK1161","159938","09939","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662678970","title":"港股异动 | 礼邦医药-B(09637)涨超6% 公司入通预期与业绩窗口有望形成双重催化 美信罗商业化放量可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2662678970","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662678970?lang=zh_cn&edition=full","pubTime":"2026-08-25 14:52","pubTimestamp":1787640722,"startTime":"0","endTime":"0","summary":"值得注意的是，公司将于8月26日披露上市后首份中期业绩，入通预期与业绩窗口有望形成双重催化。华泰证券研报指出，礼邦医药-B此前与罗氏达成关于美信罗的独家商业化合作，是公司目前唯一实现商业化上市的产品。该行预计美信罗有望于2034年在中国实现约10亿元人民币的销售峰值，考虑因素有中国长效制剂渗透率有望持续提升；公司已组建成熟的商业化团队，为产品推广提供有力支撑；以及罗氏供应瓶颈解决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484924.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","KCAI","BK4588","BK1161","BK1191","VXUS","BK1515","159938","BK1574","09637","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661326717","title":"获纳入恒生综指 礼邦医药-B(09637.HK)有望跻身港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2661326717","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661326717?lang=zh_cn&edition=full","pubTime":"2026-08-21 19:26","pubTimestamp":1787311583,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","09637","BK1515","BK1191","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164312475","title":"礼邦医药-B：Tencent Holdings Limited增持，好仓比例升至10.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164312475","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164312475?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:11","pubTimestamp":1787303498,"startTime":"0","endTime":"0","summary":"Tencent Holdings Limited于2026年8月17日以每股均价32.3366港元买入礼邦医药-B股份3.10万股，涉资约100.24万港元。Tencent Holdings Limited此次增持前持有礼邦医药-B好仓2353.56万股，占比9.99%；增持后持股量为2356.66万股，好仓比例升至10.0%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198136493","title":"礼邦医药-B（09637）临时股东会通过审计师委任及股份发行、回购授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1198136493","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198136493?lang=zh_cn&edition=full","pubTime":"2026-08-14 18:22","pubTimestamp":1786702925,"startTime":"0","endTime":"0","summary":"8月14日，礼邦医药-B公布其于2026年8月14日举行的临时股东会投票结果，全部议案均获股东高票通过。此次会议共有348,365,531股具表决权股份获准参与投票，公司董事会成员全部以现场或电子方式出席会议。公告同时披露，截至EGM召开日，公司无任何库存股份或待注销的回购股份，亦不存在股东受限投票或需放弃投票的情形。截至公告日，礼邦医药-B董事会由4名执行董事、1名非执行董事及3名独立非执行董事组成。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178604628","title":"礼邦医药-B（09637）董事会定于2026年8月26日审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1178604628","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178604628?lang=zh_cn&edition=full","pubTime":"2026-08-13 19:42","pubTimestamp":1786621361,"startTime":"0","endTime":"0","summary":"礼邦医药-B（09637）8月13日公告称，公司董事会将于2026年8月26日（星期三）召开会议，届时将审议并批准集团截至2026年6月30日止六个月的中期业绩及其发布事宜。公告显示，截至公告日期，公司董事会由8名成员组成，包括4名执行董事──Gavin Guoyao Xia博士、Jin Tian医生、汪昀女士及张华丁博士；1名非执行董事鲁安博士；以及3名独立非执行董事徐润红博士、Zhui Chen博士及梁智维先生。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659135560","title":"【券商聚焦】华泰证券首予礼邦医药（09637）买入评级 指肾病管线卡位优","url":"https://stock-news.laohu8.com/highlight/detail?id=2659135560","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659135560?lang=zh_cn&edition=full","pubTime":"2026-08-13 13:52","pubTimestamp":1786600358,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券发布研报指，首次覆盖礼邦医药-B 并给予“买入”评级，目标价51.86港元。据CIC数据，2025年全球高磷血症药物市场规模达18亿美元，2035年有望达64亿美元，且全球仅有这两个创新管线。2023年公司与罗氏达成独家商业化合作，华泰预计美信罗有望于2034年在中国实现约10亿元人民币销售峰值，考虑中国长效制剂渗透率提升、成熟商业化团队支撑以及罗氏供应瓶颈解决。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/YzMzOTE1NTA2MzA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988115","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09637","09939","KCE","159938"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alebund.com","stockEarnings":[{"period":"1week","weight":-0.028},{"period":"1month","weight":-0.2065},{"period":"3month","weight":-0.0204},{"period":"6month","weight":0.1053},{"period":"ytd","weight":0.1053}],"compareEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":-0.0373},{"period":"3month","weight":0.0676},{"period":"6month","weight":-0.02},{"period":"1year","weight":-0.0835},{"period":"ytd","weight":-0.0397}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"礼邦医药（江苏）股份有限公司是一家主要从事生物制药的中国公司。该公司的临床及临床前产品组合由一款核心产品AP301及其他候选产品组成，包括：一款临床后期候选产品（AP306）、一款临床前期候选药物（AP303），以及四款临床前候选药物（AP308、AP304、AP305与AP307）。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"礼邦医药-B","nameEN":"ALEBUND-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"礼邦医药-B(09637)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供礼邦医药-B(09637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"礼邦医药-B,09637,礼邦医药-B股票,礼邦医药-B股票老虎,礼邦医药-B股票老虎国际,礼邦医药-B行情,礼邦医药-B股票行情,礼邦医药-B股价,礼邦医药-B股市,礼邦医药-B股票价格,礼邦医药-B股票交易,礼邦医药-B股票购买,礼邦医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"礼邦医药-B(09637)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供礼邦医药-B(09637)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}